A Cross-sectional Study on Prevalence of Pain and Breakthrough Pain Among an Unselected Group of Outpatients in a Tertiary Cancer Clinic
Overview
Oncology
Affiliations
Purpose: Systematic knowledge about the prevalence and the treatment effects of cancer pain in patients attending a general oncology outpatient department is limited. The purpose of this study was to investigate the prevalence of pain in a large representative cohort of patients attending a general oncology outpatient department in order to guide further screening, classification, and treatment of pain.
Material And Methods: A cross-sectional study among patients visiting the outpatient clinic with histologically verified cancer, age≥18 years, adequate cognitive function, and no surgical procedures last 24 h were included. Pain was assessed by the Brief Pain Inventory and the Alberta Breakthrough Pain Assessment Tool.
Results: Three hundred five patients were included. The mean age was 60 years, 94% had a WHO performance status of 0-1 and 59% received oncological treatment with a curative intent. The mean score for average pain last 24 h (numerical rating scale, 0-10) and current pain was 1.84 and 1.08, respectively. Twenty-two percent reported pain score of ≥4 as their average pain in the previous 24 h. Twenty-one percent reported breakthrough pain (BTP). In multivariate analyses, sleep, BTP, age, treatment intent, and comorbidity was significantly associated with mean average pain in the previous 24 h and explained 29% of the variability of average pain in the previous 24 h.
Conclusion: Of the patients at an oncology outpatient clinic, 22% reported clinically significant pain. These findings indicate that all patients are candidates to be screened for pain and, if present, a more detailed pain diagnosis should be established before any interventions can be recommended.
Tekie Y, Nigatu Y, Mekonnen W, Berhe Y Front Oncol. 2024; 13:1248921.
PMID: 38264754 PMC: 10805268. DOI: 10.3389/fonc.2023.1248921.
Porzio G, Capela A, Giusti R, Lo Bianco F, Moro M, Ravoni G Drugs Context. 2023; 12.
PMID: 37077766 PMC: 10108666. DOI: 10.7573/dic.2022-11-7.
High-rate breakthrough cancer pain and tumour characteristics - literature review and case series.
Cuomo A, Boutis A, Colonese F, Nocerino D Drugs Context. 2023; 12.
PMID: 36926050 PMC: 10012833. DOI: 10.7573/dic.2022-11-1.
Snijders R, Brom L, Theunissen M, van den Beuken-van Everdingen M Cancers (Basel). 2023; 15(3).
PMID: 36765547 PMC: 9913127. DOI: 10.3390/cancers15030591.
Shkodra M, Brunelli C, Zecca E, Infante G, Miceli R, Caputo M Palliat Med. 2022; 36(9):1396-1407.
PMID: 36113091 PMC: 9606010. DOI: 10.1177/02692163221122354.